Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Free Cash Flow (2020 - 2025)

Maxcyte (MXCT) has disclosed Free Cash Flow for 6 consecutive years, with -$4.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 53.08% to -$4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$36.2 million through Dec 2025, down 23.64% year-over-year, with the annual reading at -$36.2 million for FY2025, 23.64% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$4.4 million at Maxcyte, up from -$7.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $9.8 million in Q4 2022, with the low at -$15.1 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$5.7 million, with a median of -$5.8 million recorded in 2021.
  • Peak annual rise in Free Cash Flow hit 991.74% in 2022, while the deepest fall reached 2302.67% in 2022.
  • Over 5 years, Free Cash Flow stood at -$1.1 million in 2021, then surged by 991.74% to $9.8 million in 2022, then plummeted by 92.86% to $702000.0 in 2023, then tumbled by 1444.3% to -$9.4 million in 2024, then surged by 53.08% to -$4.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$4.4 million, -$7.4 million, and -$9.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.